Chondroitin sulfate and sulfur containing chondroprotective agents: Is there a basis for their pharmacological action?

Current Rheumatology Reviews

Volumn 2, Issue 2, 2006, Pages 137-149

  Nimni, Marcel E ^a   Cordoba, Fabiola ^a   Strates, Basil ^b   Han, Bo ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Arthritis; Cartilage; Chondrocyte; Chondroitin sulfate; Glutathione; Glycosaminoglycans; Sulfur

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CHONDROITIN SULFATE; CHONDROPROTECTIVE AGENT; CYSTEINE; DIMERCAPROL; DIMETHYL SULFONE; DIMETHYL SULFOXIDE; GLUCOSAMINE SULFATE; GLUTATHIONE; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN PEPTIDE; METHIONINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; S ADENOSYLMETHIONINE; SODIUM THIOSULFATE; SULFUR DERIVATIVE; THIOL DERIVATIVE;

AMINO ACID DEFICIENCY; ARTHRALGIA; CARBOHYDRATE SYNTHESIS; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG DEGRADATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG UTILIZATION; ENTEROPATHY; HOMEOSTASIS; HUMAN; INFLAMMATION; KNEE PAIN; NONHUMAN; NUTRITIONAL REQUIREMENT; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT; REVIEW;

EID: 33745891185     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339706776876017     Document Type: Review

References (88)

1. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000; 60: 6-8.
2. Hungin AP, Kean WF. Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis? Am J Med 2001; 1 10(1A): 8S-11S.
3. Manek NJ. Medical management of osteoarthritis. Mayo Clin Proc 2001; 76(5): 533-9.
4. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001; 60(2): 91-7.
5. Jimenez SA, Dharmavaram RM. Genetic aspects of familial osteoarthritis. Ann Rheum Dis 1994; 53(12): 789-97.
6. Mankin HJ. Biochemical and metabolic abnormalities in osteoarthritic human cartilage. Fed Proc 1973; 32(4): 1478-80.
7. Mankin HJ. Metabolic bone disease. Instr Course Lect 1995; 44: 3-29.
8. Maroudas A. Distribution and diffusion of solutes in articular cartilage. Biophys J 1970; 10(5): 365-79.
9. Kalbhen DA. Analytical investigations of the cartilage extract in Rumalon. Med Pharmacol Exp Int J Exp Med 1966; 15(4): 344-50.
10. Borda I.a.R.K. NSAIDs: a Profile of Adverse Effects. 1992: Mosby-year book, Inc. 25-80.
11. McGee P. Growing interest in glucosamine leads NIH to fund study. Orthopedics Today; 2001(26).
12. Biggee BA, McAlindon T. Glucosamine for osteoarthritis: part I, review of the clinical evidence. Med Health R I 2004; 87(6): 176-9.
13. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283(11): 1469-75.
14. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25(2): 379-95.
15. Towheed TE, Anastassiades TP. Glucosamine therapy for osteoarthritis. J Rheumatol 1999; 26(11): 2294-7.
16. Cohen, M., R. Wolfe, T. Mai, D. Lewis. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003; 30(3): 523-8.
17. Hauselmann HJ. Nutripharmaceuticals for osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15(4): 595-607.
18. Curtis CL, Harwood JL, Dent CM, Caterson B. Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today 2004; 9(4): 165-72.
19. Biggee BA, McAlindon T. Glucosamine for osteoarthritis: part II, biologic and metabolic controversies. Med Health R I 2004; 87(6): 180-1.
20. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev 2002; 7(l): 22-44.
21. Martin JA, Buckwalter JA. Human chondrocyte senescence and osteoarthritis. Biorheology 2002; 39(1-2): 145-52.
22. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001; 50(7): 767-70.
23. Setnikar I, Giachetti C, Zanolo G, Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. Pharmatherapeutica 1984; 3(8): 538-50.
24. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993; 43(10): 1109-13.
25. Hannan MT, Tucker KL, Dawson-Hughes B, et al. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15(12): 2504-12.
26. Munger RG, Cerhan JR, Chin BC. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr 1999; 69(l): 147-52.
27. Sellmeyer DE, Stone KL, Sebastian A, Cummings SR. A high ratio of dietary animal to vegetable protein increases the rate of bone loss and the risk of fracture in postmenopausal women. Study of Osteoporotic Fractures Research Group. Am J Clin Nutr 2001; 73(l): 118-22.
28. Griffith, O.W., Mammalian sulfur amino acid metabolism: an overview. Methods Enzymol 1987; (143: 366-76).
29. Campbell WW, Crim MC, Dallal GE, Young VR, Evans WJ. Increased protein requirements in elderly people: new data and retrospective reassessments. Am J Clin Nutr 1994; 60(4): 501-9.
30. Wretlind KA, Rose WC. Methionine requirement for growth and utilization of its optical isomers. J Biol Chem 1950; 187(2): 697-703.
31. Rose WC, Wixom RL. The amino acid requirements of man. XIII. The sparing effect of cystine on the methionine requirement. J Biol Chem 1955; 216(2): 753-73.
32. Crim M.a.M, HN. Proteins and Amino Acids, in Modern Nutrition in Health and Disease, ed. O.J.a.S.M. Shils ME. 1994; Baltimore: Williams & Wilkins.
33. Tuttle SG, Bassett SH, Griffith WH, Mulcare DB, Swendseid ME. Further Observations on the Amino Acid Requirements of Older Men. Ii. Methionine and Lysine. Am J Clin Nutr 1965; 16: 229-31.
34. Fukagawa, NK, Yu YM, Young VR. Methionine and cysteine kinetics at different intakes of methionine and cysteine in elderly men and women. Am J Clin Nutr 1998; 68(2): 380-8.
35. Fuller MF, Garlick PJ. Human amino acid requirements: can the controversy be resolved? Annu Rev Nutr 1994; 14: 217-41.
36. Anderson JO, Warnick RE, Dalai RK. Replacing dietary methionine and cystine in chick diets with sulfate or other sulfur compounds. Poult Sci 1975; 54(4): 1122-8.
37. Schutte J.B.a.P., M. Effects of dietary sulphur-containing amino acids on performance and breast meat deposition of broiler chicks during the growing and finishing phases. Br Poult Sci 1995; 36(5): 747-62.
38. Lin JH, Levy G. Renal clearance of inorganic sulfate in rats: effect of acetaminophen-induced depletion of endogenous sulfate. J Pharm Sci 1983; 72(3): 213-7.
39. McLean AE, Armstrong GR, Beales D. Effect of D- or L-methionine and cysteine on the growth inhibitory effects of feeding 1% paracetamol to rats. Biochern Pharmacol 1989; 38(2): 347-52.
40. Glazenburg EJ, Jekel-Halsema IM, Scholtens E, Baars AJ, Mulder GJ. Effects of variation in the dietary supply of cysteine and methionine on liver concentration of glutathione and "active sulfate" (PAPS) and serum levels of sulfate, cystine, methionine and taurine: relation to the metabolism of acetaminophen. J Nutr 1983; 113(7): 1363-73.
41. Rozman P, Kim HJ, Madhu C, Gregus Z, Klaassen CD. Homeostasis of sulfate and 3'-phosphoadenosine 5'-phosphosulfate in rats with deficient dietary intake of sulfar. Drug Metab Dispos 1992; 20(3): 374-8.
42. Gregus, Z, Kim HJ, Madlm C, et al. Sulfation of acetaminophen and acetaminophen-induced alterations in sulfate and 3'-phosphoadenosine 5'-phosphosulfate homeostasis in rats with deficient dietary intake of sulfur. Drug Metab Dispos 1994; 22(5): 725-30.
43. Townsend DM, Tew KD,Tapiero H. Sulfur containing amino acids and human disease. Biomed Pharmacother 2004; 58(l): 47-55.
44. Tateishi N, Higashi T, Naruse A, Hikita K, Sakamoto Y. Relative contributions of sulfur atoms of dietary cysteine and methionme to rat liver glutathione and proteins. J Biochem (Tokyo) 1981; 90(6): 1603-10.
45. Breitkreutz R, Babylon A, Hack V, et al. Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. Br J Cancer 2000; 82(2): 399-403.
46. Droge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000; 59(4): 595-600.
47. Ekmekcioglu C, Strauss-Blasche G, Holzer F, Marktl W. Effect of sulfur baths on antioxidative defense systems, peroxide concentrations and lipid levels in patients with degenerative osteoarthritis. Forsch Komplementarmed Klass Naturheilkd 2002; 9(4): 216-20.
48. Scheidleder B, Holzer F, Marktl W. Effect of sulfur administration on lipid levels, antioxidant status and peroxide concentration in health resort patients]. Forsch Komplementarmed Klass Naturheilkd 2000; 7(2): 75-8.
49. Boebel KP, Baker DH. Blood and liver concentrations of glutathione, and plasma concentrations of sulfur-containing amino acids in chicks fed deficient, adequate, or excess levels of dietary cysteine. Proc Soc Exp Biol Med 1983; 172(4): 498-501.
50. Jones DP, Carlson JL, Mody VC, et al. Redox state of glutathione in human plasma. Free Radic Biol Med 2000; 28(4): 625-35.
51. Cho ES, Johnson N, Snider BC. Tissue glutathione as a cyst(e)ine reservoir during cystine depletion in growing rats. J Nutr 1984; 114(10): 1853-62.
52. Erden-Inal M, Sunal E, Kanbak G. Age-related changes in the glutathione redox system. Cell Biochem Funct 2002; 20(l): 61-6.
53. Richmond VL. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. Life Sci 1986; 39(3): 263-8.
54. Hoshi T, Heinemann S. Regulation of cell function by methionine oxidation and reduction. J Physiol 2001; 531(Pt 1): 1-11.
55. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J 2004; 45(5): 776-88.
56. Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthri Cartil 2003; 11(3): 228-30.
57. Berglund F, Sorbo B. Turbidimetric analysis of inorganic sulfate in serum, plasma and urine. Scand J Clin Lab Invest 1960; 12: 147-53.
58. Dohlman CH. The fate of the sulfate group of chondroitin sulfate after administration to rats. Acta Physiol Scand 1956; 37(2-3): 220-34.
59. Benincosa LJ, Sagawa K, Morris ME. Renal adaptation to altered dietary sulfate in rats. J Pharmacol Exp Ther 1995; 272(l): 248-55.
60. Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J 1993; 54(10): 615-27.
61. Florin T, Neale G, Gibson GR, Christl SU, Cummings JH. Metabolism of dietary sulphate: absorption and excretion in humans. Gut 1991; 32(7): 766-73.
62. Mroz PJ, Silbert JE. Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum 2004; 50(11): 3574-9.
63. Barthe L, Woodley J, Lavit M, et al. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung 2004; 54(5): 286-92.
64. Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv 2004; 11(2): 129-48.
65. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthri Cartil 2003; 11(6): 433-41.
66. Bobacz K, Erlacher L, Graninger WB. The effect of Condrosulf (sodium chondroitin sulfate) on proteoglycan synthesis by human osteoarthritic an bovine juvenile articular cartilage chondrocytes--an in vitro study]. Acta Mod Austriaca 2002; 29(l): 20-5.
67. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004; 134(3): 489-92.
68. Margalit A, Hauser SD, Zweifel BS, Anderson MA, Isakson PC. Regulation of prostaglandin biosynthesis in vivo by glutathione. Am J Physiol 1998; 274(2 Pt 2): R294-302.
69. Lyons J, Rauh-Pfeiffer A, Yu YM, et al. Blood glutathione synthesis rates in healthy adults receiving a sulfur amino acid-free diet. Proc Natl Acad Sci USA 2000; 97(10): 5071-6.
70. Grimble RF, Grimble GK. Immunonutrition: role of sulfur amino acids, related amino acids, and polyamines. Nutrition 1998; 14(7-8):605-10.
71. Cole DE, Evrovski J. The clinical chemistry of inorganic sulfate. Crit Rev Clin Lab Sci 2000; 37(4): 299-344.
72. Bradley H, Gough A, Sokhi RS, et al. Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. J Rheumatol 1994; 21(7): 1192-6.
73. van der Kraan PM, de Vries BJ, Vitters EL, van den Berg WB, van de Putte LB. The effect of low sulfate concentrations on the glycosaminoglycan synthesis in anatomically intact articular cartilage of the mouse. J Orthop Res 1989; 7(5): 645-53.
74. Lammi MJ, Qu CJ, Laasanen MS, et al. Undersulfated chondroitin sulfate does not increase in osteoarthritic cartilage. J Rheumatol 2004; 31(12): 2449-53.
75. Halstead PK, Roe DA. Effect of salicylamide on skeletal glycosaminoglycan sulfation and calcification in fetal rat limbs. Drug Nutr Interact 1981; 1(1): 75-86.
76. van der Kraan PM, Vitters EL, de Vries BJ, van den Berg WB. High susceptibility of human articular cartilage glycosaminoglycan synthesis to changes in inorganic sulfate availability. J Orthop Res 1990; 8(4): 565-7 1.
77. van der Kraan PM, Vitters EL, de Vries BJ, van den Berg WB, van de Putte LB, The effect of chronic paracetamol administration to rats on the glycosaminoglycan content of patellar cartilage. Agents Actions 1990; 29(3-4): 218-23.
78. Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm Drug Dispos 2004; 25(3): 109-16.
79. Krijgsheld KR, Glazenburg EJ, Scholtens E, Mulder GJ. The oxidation of L- and D-cysteine to inorganic sulfate and taurine in the rat. Biochim Biophys Acta 1981; 677(l): 7-12.
80. Hartmann F. Percutaneous resorption of antirheumatic substances]. Z Rheumaforsch 1968; 27(l): 12-9.
81. Callies R. [Aspects of differential balneotherapy in rheumatic diseases]. Z Physiother 1971; 23(6): 397-409.
82. Sukenik S, Buskila D, Neumann L, et al. Sulphur bath and mud pack treatment for rheumatoid arthritis at the Dead Sea area. Ann Rheum Dis 1990; 49(2): 99-102.
83. Sukenik S. Balneotherapy for rheumatic diseases at the Dead Sea area. Isr J Med Sci 1996; 32 Suppl: S16-9.
84. Silbert CK, Palmer ME, Humphries DE, Silbert JE. Production of [3H]hexosamine-labeled proteoglycans by cultures of normal and diabetic skin fibroblasts: dilution of exogenous [3H]glucosamine by endogenous hexosamine from glucose and other sources. Arch Biochern Biophys 1989; 268(l): 393-7.,
85. Humphries DE, Silbert CK, Silbert JE. Sulphation by cultured cells. Cysteine, cysteinesulphinic acid and sulphite as sources for proteoglycan sulphate. Biochern J 1988; 252(l): 305-8.
86. Imai Y, Yanagishita M, Hascall VC. Measurement of contribution from intracellular cysteine to sulfate in phosphoadenosine phosphosulfate in rat ovarian granulosa cells. Arch Biochern Biophys 1994; 312(2): 392-400.
87. Davidson S.a.P., R. Human Nutrition and Dietetics 1959: Williams and Wilkins, Baltimor.
88. Karanja N, Erlinger TP, Pao-Hwa L, Miller ER, 3rd, Bray GA. The DASH diet for high blood pressure: from clinical trial to dinner table. Cleve Clin J Med 2004; 71(9): 745-53.